Shivom. ICO.

This ecosystem will provide confidentiality of all data, while protecting each user from the cyber criminals, Shivom will use modern blockchain technology. In order for this project to become available and real in the growing market of modern technologies, the researchers of the Shivon project plan to use artificial intelligence, which will form the basis of the entire system, open web markets for other providers such as pharmaceuticals, research organizations, governments, patient support groups and insurance companies to add their applications and services, along with personalized genome and drug data analytics.

Shivom pioneered the omics ecosystem to make this vision a reality by offering its first-of-its-first investment proposition in a rapidly growing market for personalized medicine, backed by state-of-the-art blockchain technology and to improve the health services available safely and accessible to all. build sophisticated drug discovery. Shivom researchers will use data-driven tools and techniques, especially machine learning methods that support artificial intelligence, which will offer promise in improving health care systems and services around the world.

Genomic sequencing provides many benefits:

Identifying the best course of care for patients with a particular condition
Prevention of disease in healthy individuals
Prediction of disease risk
Disease diagnosis
Treatment, including choice of most effective medication and dosage
Disease prognosis
Identifying new drug targets

Shivom Platform

Genomics and artificial intelligence show a novel chance to reform R&D programs, particularly screening for medicate targets and comparing drug hopefuls. The critical cost related with tranquilize advancement is connected to the capacity to get to high caliber and approved datasets from patients. We are as of now captivating with accomplices in driving pharmaceutical/biotech organizations and clinical research associations (CROs) to enable access to our administrations, and in addition offer the chance to support genomic testing on a mass level. The information won't be claimed by any organization, and the Shivom stage will encourage pharmaceutical organizations' utilization of the information by giving alluring rewards and a market get to display that straightforwardly draws in with information proprietors. The model will enable access to study and control patients through an application commercial center for phenotypic screening and that's only the tip of the iceberg.

It will be powered by blockchain to ensure the utmost security and privacy of every record added to the system’s distributed database. People signed up to the platform will be able to upload their genomic information to Shivom’s database and receive some reward for doing so. It is not a problem if you do not have your genomic info because in such a case, Shivom will send you one of the two DNA collection kits (an exome kit or a whole genome sequencing kit to choose from) to collect your saliva sample. Then you mail this kit with your DNA sample back to Shivom. Together with partner laboratories, Shivom will thoroughly analyze your DNA and send you your health report in your platform account.

The Shivom platform uses blockchain technology to create genomes that disrupt ecosystems. This ensures the data is owned by the data donor itself. This ensures a transparent and secure bridge for organizations interested in using the data.

Donors of genome data have their data and access rights
Donors get rewarded for sharing their genomic data on blockchain by selling direct access rights to third parties institutions such as pharmaceutical companies
Pharmaceutical companies use the Shivom platform to fix drugs development
Shivom users have full and smooth controls that can access data even after third-party agencies have access to it
Patient gets personalized health, wellbeing, and lifestyle information
A dynamic ecosystem is created and continually perfected where communities can identify and remove healthy roadblocks before they become serious.

OUR VISION

1.Accelerate the age of genomics
Every one of the 7.6 billion people on earth has a unique code held within their genes that unlocks the secrets to appearance, ancestry, intellectual capabilities, health, and fitness. But, this code’s ability to reveal predisposition to disease has been overlooked.

2.Improve global health
Now is the time for concerted, community-wide development for the “genomical” challenges of the coming decade. Currently, a few key players hold the monopoly on genomic data and make huge profits from selling it to 3rd parties, usually without sharing the earnings with the data donor.

3.Jumpstart genome-based precision medicine
We are changing the dynamics of the global healthcare market. We are utilizing the most advanced technologies including blockchain, cloud computing, genome sequencing, artificial intelligence, and big data analytics to bring medical genomics into a new era.

4.Ensure the next level of data privacy
We are at the forefront of data security. We use state-of-the-art cryptography to add additional security levels to our platform that go well beyond blockchain technology for decentralization, protecting each user’s data from cybercriminals

The OmiX Token

The OmiX token is a key component that enables buying, trading, incentivizing and other services. The token is the fuel of the Shivom ecosystem, as well as part of the governance of the system. Shivom will distribute 3 billion OmiX tokens.

Token distribution

3 billion of OmiX tokens will be distributed in the following way:

990M to be sold during their ICO event
90M meant for the community (bounty programs, developers reward, ecosystem growth)
420M to support the founders
300M for early backers and advisors
600M for the data generation rewards
600M to be reserved
If they manage to achieve the fundraising goal, the received funds will be allocated as below:

25% for partnership with different laboratories
21% for marketing purposes
20% for the further platform development
11% for day-to-day processes and business development
10% for a non-profit R&D center
6% for data storage
5% for the legal compliance
2% to conduct initial PoC in the Indian hospitals

Team

Dr. Axel Schumacher is a co-founder and CEO of Shivom, a holder of the doctorate degree in genetics, boasts years of successful experience in genomics, biotechnologies, aging and longevity research.
Gourish Singla is a co-founder and COO. Has vast competence in investment banking and health management. He also founded three prosperous companies in the digital health environment.
Sally Eaves is a co-founder and CMO. Having years of expertise in a role of a chief technology officer, she can answer any question about blockchain, AI, machine learning, and robotics. Above all, she is one of top 10 blockchain and social media influencers in the world.
Akash Gaurav is Shivom’s co-founder and CTO. As a distributed ledger expert, he started the first blockchain company in India that is now one of the hugest blockchain companies around the globe. Akash helps businesses to deploy blockchain technologies.

More information:

WEBSITE:https://shivom.io/
WHITEPAPER:https://shivom.io/files/Shivom-Executive-Summary.pdf
ANN THREAD:https://bitcointalk.org/index.php?topic=2365709.msg24124494#msg24124494
FACEBOOK:https://www.facebook.com/ProjectShivom
TELEGRAM:https://t.me/projectshivom
TWITTER:https://twitter.com/projectshivom
MEDIUM:https://medium.com/@projectshivom
LINKEDIN:https://www.linkedin.com/company/project-shivom
YOUTUBE:https://www.youtube.com/c/ProjectShivom
REDDIT:https://www.reddit.com/r/Shivom/
INSTAGRAM:https://www.instagram.com/projectshivom

Author: https://bitcointalk.org/index.php?action=profile;u=1661908